Skip to main content
Top
Published in: Cancer Cell International 1/2020

01-12-2020 | Prostate Cancer | Primary research

Establishment and characterization of stable red, far-red (fR) and near infra-red (NIR) transfected canine prostate cancer cell lines

Authors: Wen Liu, Sina Sender, Weibo Kong, Julia Beck, Anett Sekora, Kirsten Bornemann-Kolatzki, Ekkehart Schuetz, Christian Junghanss, Bertram Brenig, Ingo Nolte, Hugo Murua Escobar

Published in: Cancer Cell International | Issue 1/2020

Login to get access

Abstract

Background

Canine prostate cancer represents a unique model for human prostate cancer. In vitro systems offer various possibilities but Xenograft in vivo imaging allows studying complex tasks as tumor progression and drug intervention longitudinal. Herein, we established three canine prostate carcinoma cell lines stably expressing fluorescent proteins allowing deep tissue in vivo imaging.

Methods

Three canine prostate carcinoma (cPC) cell lines were stably transfected with fluorescent proteins in red, far-red and near infra-red spectrum, followed by G418 selection. Fluorescent protein expression was demonstrated by microscopy, flow cytometry and a NightOWL LB 983 in vivo imaging system. Cellular and molecular characteristics of the generated cell lines were compared to the parental cell line CT1258. Cell proliferation, metabolic activity and sphere formation capacity were analyzed. Stem cell marker expression was examined by qPCR and genomic copy number variation by genomic DNA whole genome sequencing.

Results

Three stably fluorescent protein transfected cPC cell lines were established and characterized. Compared to the parental cell line, no significant difference in cell proliferation and metabolic activity were detected. Genomic copy number variation analyses and stem cell marker gene expression revealed in general no significant changes. However, the generated cell line CT1258-mKate2C showed uniquely no distal CFA16 deletion and an elevated metabolic activity. The introduced fluorescencent proteins allowed highly sensitive detection in an in vivo imaging system starting at cell numbers of 0.156 × 106. Furthermore, we demonstrated a similar sphere formation capacity in the fluorescent cell lines. Interestingly, the clone selected CT1258-mKate2C, showed increased sphere formation ability.

Discussion

Starting from a well characterized cPC cell line three novel fluorescent cell lines were established showing high cellular and molecular similarity to the parental cell line. The introduction of the fluorescent proteins did not alter the established cell lines significantly. The red fluorescence allows deep tissue imaging, which conventional GFP labeling is not able to realize.

Conclusion

As no significant differences were detected between the established cell lines and the very well characterized parental CT1258 the new fluorescent cell lines allow deep tissue in vivo imaging for perspective in vivo evaluation of novel therapeutic regimens.
Appendix
Available only for authorised users
Literature
1.
go back to reference Argyle DJ. Prostate cancer in dogs and men: a unique opportunity to study the disease. Vet J. 2009;180(2):137–8.PubMedCrossRef Argyle DJ. Prostate cancer in dogs and men: a unique opportunity to study the disease. Vet J. 2009;180(2):137–8.PubMedCrossRef
2.
go back to reference Lawrence JA and Saba CF. Tumors of the Male Reproductive System. In: Withrow and MacEwen’s Small Animal Clinical Oncology, 5th Edition, edn., DMV Stephen J. Withrow, Rodney L. Page, ed., St.Luois, Saunders, 2012: 575. Lawrence JA and Saba CF. Tumors of the Male Reproductive System. In: Withrow and MacEwen’s Small Animal Clinical Oncology, 5th Edition, edn., DMV Stephen J. Withrow, Rodney L. Page, ed., St.Luois, Saunders, 2012: 575.
3.
go back to reference Cornell KK, Bostwick DG, Cooley DM, Hall G, Harvey HJ, Hendrick MJ, et al. Clinical and pathologic aspects of spontaneous canine prostate carcinoma: a retrospective analysis of 76 cases. Prostate. 2000;45(2):173–83.PubMedCrossRef Cornell KK, Bostwick DG, Cooley DM, Hall G, Harvey HJ, Hendrick MJ, et al. Clinical and pathologic aspects of spontaneous canine prostate carcinoma: a retrospective analysis of 76 cases. Prostate. 2000;45(2):173–83.PubMedCrossRef
4.
go back to reference Leroy BE, Northrup N. Prostate cancer in dogs: comparative and clinical aspects. Vet J. 2009;180(2):149–62.PubMedCrossRef Leroy BE, Northrup N. Prostate cancer in dogs: comparative and clinical aspects. Vet J. 2009;180(2):149–62.PubMedCrossRef
5.
go back to reference Winter SF, Cooper AB, Greenberg NM. Models of metastatic prostate cancer: a transgenic perspective. Prostate Cancer Prostatic Dis. 2003;6(3):204–11.PubMedCrossRef Winter SF, Cooper AB, Greenberg NM. Models of metastatic prostate cancer: a transgenic perspective. Prostate Cancer Prostatic Dis. 2003;6(3):204–11.PubMedCrossRef
6.
go back to reference Waters DJ, Bostwick DG. The canine prostate is a spontaneous model of intraepithelial neoplasia and prostate cancer progression. Anticancer Res. 1997;17(3A):1467–70.PubMed Waters DJ, Bostwick DG. The canine prostate is a spontaneous model of intraepithelial neoplasia and prostate cancer progression. Anticancer Res. 1997;17(3A):1467–70.PubMed
7.
go back to reference Waters DJ, Sakr WA, Hayden DW, Lang CM, McKinney L, Murphy GP, et al. Workgroup 4: spontaneous prostate carcinoma in dogs and nonhuman primates. Prostate. 1998;36(1):64–7.PubMedCrossRef Waters DJ, Sakr WA, Hayden DW, Lang CM, McKinney L, Murphy GP, et al. Workgroup 4: spontaneous prostate carcinoma in dogs and nonhuman primates. Prostate. 1998;36(1):64–7.PubMedCrossRef
8.
go back to reference Axiak SM, Bigio A. Canine prostatic carcinoma. Compend Contin Educ Vet. 2012;34(10):E1–5.PubMed Axiak SM, Bigio A. Canine prostatic carcinoma. Compend Contin Educ Vet. 2012;34(10):E1–5.PubMed
9.
go back to reference Eaton CL, Pierrepoint CG. Growth of a spontaneous canine prostatic adenocarcinoma in vivo and in vitro: isolation and characterization of a neoplastic prostatic epithelial cell line, CPA 1. Prostate. 1988;12(2):129–43.PubMedCrossRef Eaton CL, Pierrepoint CG. Growth of a spontaneous canine prostatic adenocarcinoma in vivo and in vitro: isolation and characterization of a neoplastic prostatic epithelial cell line, CPA 1. Prostate. 1988;12(2):129–43.PubMedCrossRef
10.
go back to reference Thudi NK, Shu ST, Martin CK, Lanigan LG, Nadella MV, Van Bokhoven A, et al. Development of a brain metastatic canine prostate cancer cell line. Prostate. 2011;71(12):1251–63.PubMedPubMedCentral Thudi NK, Shu ST, Martin CK, Lanigan LG, Nadella MV, Van Bokhoven A, et al. Development of a brain metastatic canine prostate cancer cell line. Prostate. 2011;71(12):1251–63.PubMedPubMedCentral
11.
go back to reference LeRoy BE, Thudi NK, Nadella MV, Toribio RE, Tannehill-Gregg SH, van Bokhoven A, et al. New bone formation and osteolysis by a metastatic, highly invasive canine prostate carcinoma xenograft. Prostate. 2006;66(11):1213–22.PubMedCrossRef LeRoy BE, Thudi NK, Nadella MV, Toribio RE, Tannehill-Gregg SH, van Bokhoven A, et al. New bone formation and osteolysis by a metastatic, highly invasive canine prostate carcinoma xenograft. Prostate. 2006;66(11):1213–22.PubMedCrossRef
12.
go back to reference Anidjar M, Villette JM, Devauchelle P, Delisle F, Cotard JP, Billotey C, et al. In vivo model mimicking natural history of dog prostate cancer using DPC-1, a new canine prostate carcinoma cell line. Prostate. 2001;46(1):2–10.PubMedCrossRef Anidjar M, Villette JM, Devauchelle P, Delisle F, Cotard JP, Billotey C, et al. In vivo model mimicking natural history of dog prostate cancer using DPC-1, a new canine prostate carcinoma cell line. Prostate. 2001;46(1):2–10.PubMedCrossRef
13.
go back to reference Simmons JK, Dirksen WP, Hildreth BE 3rd, Dorr C, Williams C, Thomas R, et al. Canine prostate cancer cell line (Probasco) produces osteoblastic metastases in vivo. Prostate. 2014;74(13):1251–65.PubMedPubMedCentralCrossRef Simmons JK, Dirksen WP, Hildreth BE 3rd, Dorr C, Williams C, Thomas R, et al. Canine prostate cancer cell line (Probasco) produces osteoblastic metastases in vivo. Prostate. 2014;74(13):1251–65.PubMedPubMedCentralCrossRef
14.
go back to reference Azakami D, Nakahira R, Kato Y, Michishita M, Kobayashi M, Onozawa E, et al. The canine prostate cancer cell line CHP-1 shows over-expression of the co-chaperone small glutamine-rich tetratricopeptide repeat-containing protein α. Vet Comp Oncol. 2017;15(2):557–62.PubMedCrossRef Azakami D, Nakahira R, Kato Y, Michishita M, Kobayashi M, Onozawa E, et al. The canine prostate cancer cell line CHP-1 shows over-expression of the co-chaperone small glutamine-rich tetratricopeptide repeat-containing protein α. Vet Comp Oncol. 2017;15(2):557–62.PubMedCrossRef
15.
go back to reference Fork MA, Murua Escobar H, Soller JT, Sterenczak KA, Willenbrock S, Winkler S, et al. Establishing an in vivo model of canine prostate carcinoma using the new cell line CT1258. BMC Cancer. 2008;8:240.PubMedPubMedCentralCrossRef Fork MA, Murua Escobar H, Soller JT, Sterenczak KA, Willenbrock S, Winkler S, et al. Establishing an in vivo model of canine prostate carcinoma using the new cell line CT1258. BMC Cancer. 2008;8:240.PubMedPubMedCentralCrossRef
16.
go back to reference Sterenczak KA, Meier M, Glage S, Meyer M, Willenbrock S, Wefstaedt P, et al. Longitudinal MRI contrast enhanced monitoring of early tumour development with manganese chloride (MnCl2) and superparamagnetic iron oxide nanoparticles (SPIOs) in a CT1258 based in vivo model of prostate cancer. BMC Cancer. 2012;12:284.PubMedPubMedCentralCrossRef Sterenczak KA, Meier M, Glage S, Meyer M, Willenbrock S, Wefstaedt P, et al. Longitudinal MRI contrast enhanced monitoring of early tumour development with manganese chloride (MnCl2) and superparamagnetic iron oxide nanoparticles (SPIOs) in a CT1258 based in vivo model of prostate cancer. BMC Cancer. 2012;12:284.PubMedPubMedCentralCrossRef
17.
go back to reference Willenbrock S, Wagner S, Reimann-Berg N, Moulay M, Hewicker-Trautwein M, Nolte I, et al. Generation and characterisation of a canine EGFP-HMGA2 prostate cancer in vitro model. PLoS ONE. 2014;9(6):e98788.PubMedPubMedCentralCrossRef Willenbrock S, Wagner S, Reimann-Berg N, Moulay M, Hewicker-Trautwein M, Nolte I, et al. Generation and characterisation of a canine EGFP-HMGA2 prostate cancer in vitro model. PLoS ONE. 2014;9(6):e98788.PubMedPubMedCentralCrossRef
18.
go back to reference Terziyska N, Alves CC, Groiss V, Schneider K, Farkasova K, Ogris M, Wagner E, Ehrhardt H, Brentjens RJ, Stadt U, Horstmann M, Quintanilla-Martinez L, Jeremias I. In vivo imaging enables high resolution preclinical trials on patients’ leukemia cells growing in mice. PLoS ONE. 2012;7(12):e52798.PubMedPubMedCentralCrossRef Terziyska N, Alves CC, Groiss V, Schneider K, Farkasova K, Ogris M, Wagner E, Ehrhardt H, Brentjens RJ, Stadt U, Horstmann M, Quintanilla-Martinez L, Jeremias I. In vivo imaging enables high resolution preclinical trials on patients’ leukemia cells growing in mice. PLoS ONE. 2012;7(12):e52798.PubMedPubMedCentralCrossRef
19.
go back to reference Liu W, Moulay M, Willenbrock S, Roolf C, Junghanss C, Ngenazahayo A, et al. Comparative characterization of stem cell marker expression, metabolic activity and resistance to doxorubicin in adherent and spheroid cells derived from the canine prostate adenocarcinoma cell line CT1258. Anticancer Res. 2015;35(4):1917–27.PubMed Liu W, Moulay M, Willenbrock S, Roolf C, Junghanss C, Ngenazahayo A, et al. Comparative characterization of stem cell marker expression, metabolic activity and resistance to doxorubicin in adherent and spheroid cells derived from the canine prostate adenocarcinoma cell line CT1258. Anticancer Res. 2015;35(4):1917–27.PubMed
20.
go back to reference Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell. 2012;10(6):717–28.CrossRef Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell. 2012;10(6):717–28.CrossRef
21.
go back to reference Kim KW, Kim JY, Qiao J, Clark RA, Powers CM, Correa H, Chung DH. Dual-Targeting AKT2 and ERK in cancer stem-like cells in neuroblastoma. Oncotarget. 2019;10(54):5645–59.PubMedPubMedCentralCrossRef Kim KW, Kim JY, Qiao J, Clark RA, Powers CM, Correa H, Chung DH. Dual-Targeting AKT2 and ERK in cancer stem-like cells in neuroblastoma. Oncotarget. 2019;10(54):5645–59.PubMedPubMedCentralCrossRef
22.
go back to reference Winkler S, Murua Escobar H, Eberle N, Reimann-Berg N, Nolte I, Bullerdiek J. Establishment of a cell line derived from a canine prostate carcinoma with a highly rearranged karyotype. J Hered. 2005;96(7):782–5.PubMedCrossRef Winkler S, Murua Escobar H, Eberle N, Reimann-Berg N, Nolte I, Bullerdiek J. Establishment of a cell line derived from a canine prostate carcinoma with a highly rearranged karyotype. J Hered. 2005;96(7):782–5.PubMedCrossRef
23.
go back to reference Moulay M, Liu W, Willenbrock S, Sterenczak KA, Carlson R, Ngezahayo A, et al. Evaluation of stem cell marker gene expression in canine prostate carcinoma- and prostate cyst-derived cell lines. Anticancer Res. 2013;33(12):5421–31.PubMed Moulay M, Liu W, Willenbrock S, Sterenczak KA, Carlson R, Ngezahayo A, et al. Evaluation of stem cell marker gene expression in canine prostate carcinoma- and prostate cyst-derived cell lines. Anticancer Res. 2013;33(12):5421–31.PubMed
24.
go back to reference Scheinin I, Sie D, Bengtsson H, van de Wiel MA, Olshen AB, van Thuijl HF, et al. DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly. Genome Res. 2014;24(12):2022–32.PubMedPubMedCentralCrossRef Scheinin I, Sie D, Bengtsson H, van de Wiel MA, Olshen AB, van Thuijl HF, et al. DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly. Genome Res. 2014;24(12):2022–32.PubMedPubMedCentralCrossRef
26.
go back to reference Ferletta M, Grawe J, Hellmen E. Canine mammary tumors contain cancer stem-like cells and form spheroids with an embryonic stem cell signature. Int J Dev Biol. 2011;55(7–9):791–9.PubMedCrossRef Ferletta M, Grawe J, Hellmen E. Canine mammary tumors contain cancer stem-like cells and form spheroids with an embryonic stem cell signature. Int J Dev Biol. 2011;55(7–9):791–9.PubMedCrossRef
Metadata
Title
Establishment and characterization of stable red, far-red (fR) and near infra-red (NIR) transfected canine prostate cancer cell lines
Authors
Wen Liu
Sina Sender
Weibo Kong
Julia Beck
Anett Sekora
Kirsten Bornemann-Kolatzki
Ekkehart Schuetz
Christian Junghanss
Bertram Brenig
Ingo Nolte
Hugo Murua Escobar
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-020-01211-0

Other articles of this Issue 1/2020

Cancer Cell International 1/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine